Table 4.
Univariate/marginal model: significance of variables at a given tender point threshold with the pain response cutoff set at 2 at the tender point examination.
| Outcome variable | TP > 1 | TP > 2 | TP > 3 | TP > 4 | TP > 5 | TP > 6 | TP > 7 | TP > 8 | TP > 9 | TP > 10 | TP > 11 | TP > 12 | TP > 13 | TP > 14 | TP > 15 | TP > 16 | TP > 17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Body | |||||||||||||||||
| Muscle strength UE (PTQ extension) | ∗ | ∗ | ∗ | ∗ | ∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ||||||||
| Muscle strength UE (PTQ flexion) | ∗ | ∗ | ∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | |||||||
| Grip strength, max. | ∗∗∗ | ∗ | ∗∗ | ∗ | ∗ | ∗ | |||||||||||
| Vitality (SF-36) | ∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗ | ∗ | ||||||||
| Fatigue (FIQ) | ∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗ | ∗ | |||||||
| Rest (FIQ) | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗∗ | |||||||
| Well-being (SF-36) | ∗ | ∗ | ∗ | ||||||||||||||
| Well-being (FIQ) | ∗ | ∗ | ∗ | ∗∗ | ∗∗ | ∗ | ∗∗ | ||||||||||
| Anxiety (FIQ) | |||||||||||||||||
| Anxiety (GAD-10) | ∗ | ∗ | ∗ | ||||||||||||||
| Depression (FIQ) | |||||||||||||||||
| Depression (MDI) | ∗ | ∗ | |||||||||||||||
| Bodily pain (SF-36) | ∗ | ∗ | ∗∗ | ∗∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ||||||
| Pain intensity (FIQ) | ∗ | ∗∗ | ∗∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗∗ | |||||||
| Muscle stiffness (FIQ) | ∗ | ∗∗ | ∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗ | ∗ | ||||
| Tiredness mobility (Mob-T) | ∗ | ∗ | ∗ | ∗ | ∗∗ | ∗∗ | ∗∗ | ∗ | ∗ | ∗ | ∗ | ∗∗ | ∗∗ | ||||
| Pain detection threshold (PDT) | ∗ | ∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗∗ | |||||||
| Pain tolerance threshold (PTT) | ∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | |||||||
| Activity and participation | |||||||||||||||||
| ADL ability motor (AMPS) | ∗ | ∗∗ | ∗ | ∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗ | ∗ | |
| ADL ability process (AMPS) | ∗ | ∗ | |||||||||||||||
| Walking speed (6-MW) | ∗ | ∗∗ | ∗∗ | ∗ | ∗ | ∗ | ∗∗ | ∗ | ∗∗ | ∗∗ | ∗∗ | ∗ | |||||
| Activity limitations (FIQ) | ∗ | ∗∗ | ∗∗∗ | ∗∗ | ∗∗∗ | ∗∗ | ∗∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗ | ||||||
| Physical functioning (SF-36) | ∗ | ∗∗ | ∗ | ∗ | ∗∗ | ∗∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | |||||||
| Role physical (SF 36) | |||||||||||||||||
| Role emotional (SF-36) | |||||||||||||||||
| Social functioning (SF-36) | ∗ | ∗ | |||||||||||||||
| Work interference (BIQ) | ∗ | ∗ | |||||||||||||||
| Personal | |||||||||||||||||
| Catastrophizing (CSQ) | |||||||||||||||||
| Perceived control over pain (CSQ) | |||||||||||||||||
| Ability to decrease pain (CSQ) | ∗ | ||||||||||||||||
| Analgesics yes/no | ∗∗ | ∗ | |||||||||||||||
| NSAID | ∗ | ∗ | ∗ | ||||||||||||||
| Opioids | ∗ | ||||||||||||||||
| Antidepressants | ∗ | ∗ | |||||||||||||||
| Global measures | |||||||||||||||||
| FIQ total | ∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗∗ | ∗ | ∗∗ | |||||||
| SF-36 PCS | ∗ | ∗∗ | ∗ | ∗∗ | ∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | ∗∗∗ | |||||||
| SF-36 MCS | ∗ | ||||||||||||||||
| General health (SF-36) |
*P < 0.05; **P < 0.01; ***P < 0.001; GAD-10: generalized anxiety disorder; MDI: major depression inventory; SF-36: short-form-36 health survey; FIQ: fibromyalgia impact questionnaire; SF-36 PCS: SF-36 physical composite score; PTQ flex.: peak torque flexion; SF-36 MCS: SF-36 mental composite score; PTQ ext.: peak torque extension; CSQ: coping strategy questionnaire; PDT: pain detection threshold; AMPS: assessment of motor and process skills; PTT: pain tolerance threshold; 6-MW: 6-minute walk; BIQ: basic information questionnaire.